ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
NYSE:ADCT
Price:
4.37 USD
-0.46%
Updated:
Apr 16, 2024
ADC Therapeutics SA
Net Income
Last
Value
3-Years CAGR
5-Years CAGR
|
ADC Therapeutics SA
Net Income Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Net Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Net Income
$-155.8m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Net Income
CHf-54.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Net Income
$-153.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Net Income
CHf10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Net Income
CHf-827.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-122%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Net Income
CHf-13.3m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Net Income?
Net Income
-155.8m
USD
-155.8m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Net Income amounts to -155.8m USD.
What is ADC Therapeutics SA's Net Income growth rate?
Net Income CAGR 5Y
-5%
-5%
Over the last year, the Net Income growth was 0%. The average annual Net Income growth rates for ADC Therapeutics SA have been 14% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
